Canaccord Genuity Maintains Buy on Hims & Hers Health, Raises Price Target to $28
Canaccord Genuity Maintains Buy on Hims & Hers Health, Raises Price Target to $28
Canaccord Genuity維持對Hims & Hers Health的買入評級,將目標股價上調至28美元
Canaccord Genuity analyst Maria Ripps maintains Hims & Hers Health (NYSE:HIMS) with a Buy and raises the price target from $24 to $28.
Canaccord Genuity 分析師 Maria Ripps 維持Hims & Hers Health(紐交所:HIMS)的買入評級,並將其目標股價從24美元上調至28美元。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。